Adès, L., Le Bras, F., Sebert, M., Kelaidi, C., Lamy, T., Dreyfus, F., . . . Fenaux, P. (2012). Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies. Ferrata Storti Foundation.
Chicago Style citaatAdès, Lionel, et al. Treatment With Lenalidomide Does Not Appear to Increase the Risk of Progression in Lower Risk Myelodysplastic Syndromes With 5q Deletion. A Comparative Analysis By the Groupe Francophone Des Myelodysplasies. Ferrata Storti Foundation, 2012.
MLA citatieAdès, Lionel, et al. Treatment With Lenalidomide Does Not Appear to Increase the Risk of Progression in Lower Risk Myelodysplastic Syndromes With 5q Deletion. A Comparative Analysis By the Groupe Francophone Des Myelodysplasies. Ferrata Storti Foundation, 2012.